Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

PartnershipUpdated on 30 April 2026

Areas of Interest for international collaboration

Young Ho Kim

Chief Executive Officer at AT-31 BIO Inc.

Daegu, South Korea

About

Our goal is to develop treatments and expand the indications for our active immunosuppressive ingredient, GJK-012, to target Sjögren’s syndrome dry eye disease (via eye drops), atopic dermatitis (AD), inflammatory bowel disease (IBD), and multiple sclerosis (MS). To achieve this, we aim to to collaborate with pharmaceutical companies and researchers specializing in each of these respective fields.

Organisation

AT-31 BIO Inc.

SME

Daegu, South Korea

Similar opportunities